Please login to the form below

Not currently logged in
Email:
Password:

Frances Heller joins BMS senior management

Takes up business development role and will report to Lamberto Andreotti

Bristol-Myers Squibb has appointed Frances Heller as senior vice president, business development.

Reporting to the pharma company's CEO Lamberto Andreotti, she will also sit on the BMS senior management team.

Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.

Prior to that she served as head of strategic alliances at Novartis and before that as corporate and intellectual property counsel for Celera Genomics.

“With broad experience across both the biotech and pharmaceutical industries, I believe Fran will be an important addition to my diverse management team and to the company,” said Andreotti.

“In addition, her scientific, business and legal background, as well as her experience across therapeutic areas, will help Bristol-Myers Squibb continue to execute its strategy of finding external innovation that complements our own internal R&D pipeline and helps us bring important new medicines to patients.”

2nd October 2012

From: PME

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics